MorphoSys AG Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of MorphoSys AG Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 28 Mar 2019 | Lorem |
| Constellation’s CPI-1205, Veru’s VERU-111 efficacy evidence too premature to peg hopes for Phase Ib/II success potential in castrate-resistant prostate cancer, experts say | 27 Feb 2019 | Reynald Castaneda |
| Constellation’s BET inhibitor draws toxicity apprehension in myelofibrosis; early Phase I/II efficacy signals boost rationale for combo with Incyte’s Jakafi, experts say | 29 Jan 2019 | Mariana Lenharo |
| Hybrigenics in partnering talks with one or two of top three anti-CD38 players, other pharma for inecalcitol leukemia programme – CEO | 19 Jan 2017 | Fiona Barry |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer